Anzeige
Mehr »
Montag, 13.10.2025 - Börsentäglich über 12.000 News
Der Lithium Markt ist zurück - und Simon Clarke ist mit dabei!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CN5Q | ISIN: US91864C1071 | Ticker-Symbol: 2AB
Tradegate
09.10.25 | 15:39
1,310 Euro
+10,08 % +0,120
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BARINTHUS BIOTHERAPEUTICS PLC ADR Chart 1 Jahr
5-Tage-Chart
BARINTHUS BIOTHERAPEUTICS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
1,1501,19012.10.
1,1501,22010.10.

Aktuelle News zur BARINTHUS BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
BARINTHUS BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
01.10.Barinthus Biotherapeutics stock rating reiterated at Buy by H.C. Wainwright6
30.09.Barinthus Bio joins forces with metabolic disease biotech in reverse merger3
30.09.Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases281GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates...
► Artikel lesen
30.09.Barinthus BioTherapeutics to combine with Clywedog Therapeutics2
30.09.Barinthus Biotherapeutics plc. - 8-K, Current Report3
07.08.Barinthus Biotherapeutics GAAP EPS of -$0.524
07.08.Barinthus Biotherapeutics plc. - 10-Q, Quarterly Report1
07.08.Barinthus Biotherapeutics plc. - 8-K, Current Report-
10.06.Barinthus Biotherapeutics plc. - 8-K, Current Report3
09.06.Barinthus Biotherapeutics plc: Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025212OXFORD, GB AND GERMANTOWN, MD / ACCESS Newswire / June 9, 2025 / Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June...
► Artikel lesen
07.05.Barinthus Biotherapeutics plc. - 10-Q, Quarterly Report4
07.05.Barinthus Biotherapeutics plc. - 8-K, Current Report1
20.03.Barinthus Biotherapeutics: Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments894Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000)...
► Artikel lesen
06.03.Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11276NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.About...
► Artikel lesen
10.01.Barinthus Biotherapeutics: Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update469Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identifiedExtending...
► Artikel lesen
15.11.24Barinthus Biotherapeutics: Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion220Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. OXFORD, United...
► Artikel lesen
15.11.24Arbutus Biopharma Corporation: Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B437Significantly greater mean declines in HBsAg levels (p 23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom...
► Artikel lesen
06.11.24Barinthus Biotherapeutics: Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results198OXFORD, United Kingdom, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1